Moderna (MRNA) Shares Rally After Topping Q2 Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Moderna COVID vaccine sales forecast unchanged even as COVAX program cuts orders
August 3, 2022 7:11 AM EDTBy Michael Erman and Manas Mishra
(Reuters) - Moderna Inc on Wednesday maintained its full-year COVID-19 vaccine sales forecast of $21 billion as canceled orders from low- and middle-income nations through the COVAX program offset gains from new booster dose orders.
Moderna shares jumped nearly 17% in morning trading after the company also announced a $3 billion share buyback plan.
Moderna has begun producing a redesigned booster shot targeting both the original coronavirus as well as the BA.4 and BA.5 Omicron subvariants.
It signed a $1.74 billion deal with the U.S. government... More
Moderna (MRNA) announces new $3 billion share repurchase plan
August 3, 2022 7:11 AM EDTWith earnings, Moderna (NASDAQ: MRNA) announces a new $3 billion share repurchase plan.
Moderna (MRNA) Tops Q2 EPS by 70c, Beats on Revenue
August 3, 2022 7:02 AM EDTModerna (NASDAQ: MRNA) reported Q2 EPS of $5.24, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... MoreModerna (MRNA) August weekly 160 straddle priced for a move of 8% into quarter results
August 3, 2022 4:02 AM EDTModerna (NASDAQ: MRNA) August weekly 160 straddle priced for a move of 8% into the expected release of quarter results today after the bell.
... MoreModerna (MRNA) call put ratio 2.6 calls to 1 put into quarter results and outlook
August 2, 2022 10:30 AM EDTModerna (NASDAQ: MRNA) August weekly call option implied volatility is at 104, August is at 70; compared to its 52-week range of 58 to 97 into the expected release of quarter results after the bell on August 3.
... MoreModerna (MRNA) August weekly 160 straddle priced for a move of 8% into quarter
August 2, 2022 6:16 AM EDTModerna (NASDAQ: MRNA) August weekly 160 straddle priced for a move of 8% into the expected release of quarter results after the bell on August 3.
... MoreJPMorgan Assumes Moderna (MRNA) at Neutral
August 1, 2022 5:03 PM EDTJPMorgan analyst Jessica Fye assumes coverage on Moderna (NASDAQ: MRNA) with a Neutral rating and a price target of $165.00.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $164.09 yesterday.
... More